On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
-
REGULATORY HHS Report Puts Japan’s Drug Innovation Financing Well Behind US
July 15, 2026
-
BUSINESS iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
-
REGULATORY Japan Panel to Review Brinsupri, Hyrnuo, Inlexzo, GSK’s Hep B Med on July 27
July 14, 2026
-
REGULATORY CEA Review Group Debates Comparator Technologies, ICER Uncertainty
July 14, 2026
-
COMMENTARY A Turning Point for Pharma? Chuikyo Reform Could Open Door to Greater Industry Role
July 13, 2026
-
REGULATORY Japan to Set Up Subgroup to Flesh Out Pharma Investment Roadmap: PM
July 13, 2026
-
BUSINESS Marubeni Pharma Seeks New Growth Drivers to Hit FY2035 Sales Goal
July 10, 2026
-
BUSINESS Women Hold Nearly 1/4 of Leadership Roles at Japan’s Listed Pharmas and Wholesalers
July 10, 2026
-
ORGANIZATION FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
-
REGULATORY MHLW Study Group Proposes Six Options to Put Japan’s Patent Linkage System into Law
July 9, 2026
-
REGULATORY Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
-
REGULATORY Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
-
BUSINESS Alexion CEO Calls Japan “Special” for Rare Disease Drug Development
July 9, 2026
-
BUSINESS AstraZeneca CSO Urges Global Drug Price “Rebalancing” amid MFN Push
July 8, 2026
-
REGULATORY LDP, Ishin Near Deal on Chuikyo Reform to Bolster Drug Discovery
July 7, 2026
-
COMMENTARY DORA Use Could Expand as Japan Opens Door to “Sleep Disorders” Specialty
July 6, 2026
-
BUSINESS Tanabe to Sell Manufacturing Unit to Towa, Transfer 17 Products
July 6, 2026
-
REGULATORY Japan, US Launch Talks on Pharma GMP MRA to Ease Inspection Burden
July 3, 2026
-
BUSINESS Average Pay at 21 Japan Drug Makers Up 3.8%, Chugai Tops 13 Million Yen
July 2, 2026
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…